Dear Healthcare Professional: March, 2004

This correspondence is intended to inform you about recent changes to the prescribing information for LOVENOX® (enoxaparin sodium injection). A copy of the updated prescribing information is enclosed.

The new prescribing information for LOVENOX® provides additional information on pharmacokinetics, precautions, and dosage and administration for obese and low-weight patients and those with renal impairment.

- Information regarding the Clinical Pharmacology: Pharmacokinetics section has been revised.
  - New information about the distribution, elimination, and metabolism of enoxaparin in healthy volunteers has been incorporated.
  - A Special Populations section has been added, with subsections for Gender, Geriatric, Renal Impairment, Weight, and Hemodialysis.
  - The clearance/elimination of enoxaparin in patients with renal impairment, obese and low-weight patients, and patients on hemodialysis has been clarified.
  - Information in the Gender and Geriatric subsections remains the same as in the previous Pharmacodynamics section of the prescribing information.

- Information in the Precautions section has been revised.
  - A dosage adjustment is now recommended for patients with severe renal impairment (creatinine clearance <30 mL/min) who have increased exposure to enoxaparin.
  - No specific dosage adjustment is required in patients with mild or moderate renal impairment.
  - No specific dosage adjustment is required in low-weight patients; these patients should be observed carefully for signs and symptoms of bleeding.

- Information in the Dosage and Administration section has been revised.
  - A table has been created to provide further clarity on the recommended prophylaxis and treatment dosage regimens for patients with severe renal impairment.

We hope this information will be helpful to you in caring for your patients. If you have questions about the enclosed information, you may contact your local Aventis Pharmaceuticals Representative, call Aventis Pharmaceuticals Medical Information Services at 1-800-633-1610, or visit www.LOVENOX.com.

Please share this information with your colleagues involved in the care of patients using LOVENOX®.

Sincerely,

Francois Nader
Senior Vice President
Medical Affairs, North America

Please see Important Safety Information on reverse side.

Important Safety Information

LOVENOX® (enoxaparin sodium injection) cannot be used interchangeably with other low-molecular-weight heparins or unfractionated heparin, as they differ in their manufacturing process, molecular weight distribution, anti-Xa and anti-IIa activities, units, and dosage.

When epidural/spinal anesthesia or spinal puncture is employed, patients anticoagulated or scheduled to be anticoagulated with low-molecular-weight heparins or heparinoids are at risk of developing an epidural or spinal hematoma, which can result in long-term or permanent paralysis.

The risk of these events is increased by the use of postoperative indwelling epidural catheters or by the concomitant use of drugs affecting hemostasis. Patients should be frequently monitored for signs and symptoms of neurological impairment. (See boxed WARNING.)

As with other anticoagulants, use with extreme caution in patients with conditions that increase the risk of hemorrhage. Dosage adjustment is recommended in patients with severe renal impairment. Unless otherwise indicated, agents that may affect hemostasis should be discontinued prior to LOVENOX® therapy. Bleeding can occur at any site during LOVENOX® therapy. An unexplained fall in hematocrit or blood pressure should lead to a search for a bleeding site. (See WARNINGS and PRECAUTIONS.)

Thrombocytopenia can occur with LOVENOX®. In patients with a history of heparin-induced thrombocytopenia, LOVENOX® should be used with extreme caution. Thrombocytopenia of any degree should be monitored closely. If the platelet count falls below 100,000/mm3, LOVENOX® should be discontinued. Cases of heparin-induced thrombocytopenia have been observed in clinical practice. (See WARNINGS.)

The use of LOVENOX® has not been adequately studied for thromboprophylaxis in pregnant women with mechanical prosthetic heart valves. (See WARNINGS.)

LOVENOX® is contraindicated in patients with hypersensitivity to enoxaparin sodium, heparin, or pork products, and in patients with active major bleeding.

Please see enclosed full prescribing information, including boxed WARNING.

Visit our website, www.LOVENOX.com, for healthcare professional and patient information.